MedTrace Logo

The Effects of Metformin on Blood Vessel Structure and Function

NCT00105066 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2017-01-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate whether the drug Metformin has beneficial effects on the blood vessels of individuals with the Metabolic Syndrome (MeS).

Conditions

Interventions

DRUG

Metformin

850mg tablet once a day for one month, then twice a day for 3 months

DRUG

Placebo

placebo tablet once a day for one month, then twice a day for 3 months

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    lead NIH

Principal Investigators

  • Luigi Ferrucci, MD · National Institute on Aging (NIA)

  • James Strait, M.D., Ph.D. · National Institute on Aging (NIA)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00105066 on ClinicalTrials.gov